Moderna (MRNA) Stock Sees Modest Fair Value Lift After Cancer Vaccine Analyst Revisions

What happened: Moderna's fair value estimate rose to US$122.67 per share from US$119.56 after analyst revisions tied to its intismeran cancer vaccine program. Key numbers: Fair value US$119.56 to US$122.67. Revenue growth 26.74% to 26.75%. Net margin 17.25% to 17.20%. Future P/E 80.90x to 83.10x. Why it matters: Bulls including BofA, Goldman Sachs, UBS, Barclays, RBC Capital and Morgan Stanley lifted targets on Phase 3 INTerpath-001 melanoma data, while Citi and Rothschild & Co Redburn moved to Sell on oncology revenue assumptions and limited efficacy disclosure. Market: -5.0% by next close ($213.74 on Oct 12), +633.3% YTD

Moderna's fair value estimate rose to US$122.67 per share from US$119.56 after analyst revisions tied to its intismeran cancer vaccine program.

Bulls including BofA, Goldman Sachs, UBS, Barclays, RBC Capital and Morgan Stanley lifted targets on Phase 3 INTerpath-001 melanoma data, while Citi and Rothschild & Co Redburn moved to Sell on oncology revenue assumptions and limited efficacy disclosure. Market: -5.0% by next close ($213.74 on Oct 12), +633.3% YTD